Clinical and Translational Epidemiology Branch (CTEB)

The Clinical and Translational Epidemiology Branch (CTEB) focuses on etiologic and genomic factors that influence cancer progression, recurrence, survival, and other treatment outcomes, and factors associated with cancer development among individuals with underlying diseases and conditions.

CTEB's mission is to plan, develop, direct, coordinate, and evaluate:

• A comprehensive program of epidemiologic research in human populations related to etiologic and genomic factors that influence cancer progression, recurrence, survival, and other treatment outcomes, and factors associated with cancer development among individuals with underlying diseases and conditions;
• A program of epidemiologic research to study differences in cancer susceptibility and risk in individuals and populations and the multiple environmental and genetic factors that jointly contribute to development of cancer among individuals with underlying diseases and conditions and progression, recurrence, survival, and other treatment outcomes, and factors associated with cancer development among individuals with underlying diseases and conditions with the ultimate goal of elucidating cancer development and progression among people with these health conditions;
• A program of extramural epidemiologic research to evaluate the association of and magnitude of cancer risk associated with biomarkers of cancer development and progression in individuals with underlying diseases and cancer; and
• Resources, infrastructures, and consortia with a focus on cancer development and progression in individuals with underlying diseases and cancer to facilitate and maximize the scientific potential of cancer epidemiology research.

Its mission also is to disseminate findings from the research supported by the Branch to the public, health care professionals, scientists engaged in cancer control, and the public health community.

The populations studied in the grants in CTEB are primarily patient populations—individuals who have had cancer, have premalignant conditions or certain chronic or genetic diseases that may predispose to cancer, or have experienced certain treatments, such as immunosuppression after organ transplants, that may predispose to cancer.

CTEB Staff